Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H11NO |
| Molecular Weight | 113.1576 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1CCCC1=O
InChI
InChIKey=ZFPGARUNNKGOBB-UHFFFAOYSA-N
InChI=1S/C6H11NO/c1-2-7-5-3-4-6(7)8/h2-5H2,1H3
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24232175
http://www.ncbi.nlm.nih.gov/pubmed/3391472
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24232175
http://www.ncbi.nlm.nih.gov/pubmed/3391472
N-ethyl-2-pyrrolidone (NEP) is a colourless and highly polar liquid. It can be used as a highly effective selected solvent, catalyst and cationic surfactant in industry (e.g. coatings). NEP has been shown to display a spectrum of developmental toxic and teratogenic effects in rodents after oral administration. The oral LD50 of NEP in rats was reported to
be 1.36 g/kg. The two postulated NEP metabolites 5-hydroxy-N-ethyl-2-pyrrolidone (5-HNEP) and 2-hydroxy-N ethylsuccinimide (2-HESI) have recently been detected in urine samples from the general population.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Metabolism and elimination of N-ethyl-2-pyrrolidone (NEP) in human males after oral dosage. | 2014-04 |
|
| Chemistry of secondary polyphenols produced during processing of tea and selected foods. | 2009-12-28 |
|
| Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. | 2009-01 |
|
| Stereoselective behavior of a novel biodegradable racemic ketoprofen injectable implant in rats. | 2007-11 |
|
| Developmental toxic effects of N-ethyl-2-pyrrolidone administered orally to rats. | 2007-03-21 |
|
| Molecular dynamics and interactions of aqueous and dichloromethane solutions of polyvinylpyrrolidone. | 2006-07-21 |
|
| The acute oral toxicity and primary ocular and dermal irritation of selected N-alkyl-2-pyrrolidones. | 1988-05 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Reseachers orally dosed 20.9 mg NEP to three male volunteers. These volunteers collected all their urine samples over a period of 4 days post dose. In these samples the authors identified and quantified the above postulated NEP metabolites 5-HNEP and 2-HESI and determined their urinary elimination kinetics and their metabolic conversion factors.
20.9 mg NEP equalling an intake between 220 and 252 μg/kg b.w.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000053391
Created by
admin on Mon Mar 31 21:06:44 GMT 2025 , Edited by admin on Mon Mar 31 21:06:44 GMT 2025
|
PRIMARY | |||
|
220-250-6
Created by
admin on Mon Mar 31 21:06:44 GMT 2025 , Edited by admin on Mon Mar 31 21:06:44 GMT 2025
|
PRIMARY | |||
|
17595
Created by
admin on Mon Mar 31 21:06:44 GMT 2025 , Edited by admin on Mon Mar 31 21:06:44 GMT 2025
|
PRIMARY | |||
|
H0229SX1CW
Created by
admin on Mon Mar 31 21:06:44 GMT 2025 , Edited by admin on Mon Mar 31 21:06:44 GMT 2025
|
PRIMARY | |||
|
1551421
Created by
admin on Mon Mar 31 21:06:44 GMT 2025 , Edited by admin on Mon Mar 31 21:06:44 GMT 2025
|
PRIMARY | RxNorm | ||
|
2687-91-4
Created by
admin on Mon Mar 31 21:06:44 GMT 2025 , Edited by admin on Mon Mar 31 21:06:44 GMT 2025
|
PRIMARY | |||
|
DTXSID3044413
Created by
admin on Mon Mar 31 21:06:44 GMT 2025 , Edited by admin on Mon Mar 31 21:06:44 GMT 2025
|
PRIMARY | |||
|
H0229SX1CW
Created by
admin on Mon Mar 31 21:06:44 GMT 2025 , Edited by admin on Mon Mar 31 21:06:44 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
